Bulletin
Investor Alert

London Markets Open in:

Intellia Therapeutics Inc.

NAS: NTLA

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 23, 2022, 7:58 p.m.

/zigman2/quotes/207821052/composite

$

44.96

Change

-2.36 -4.99%

Volume

Volume 14,629

Quotes are delayed by 20 min

/zigman2/quotes/207821052/composite

Previous close

$ 47.74

$ 47.32

Change

-0.42 -0.88%

Day low

Day high

$46.48

$49.84

Open

52 week low

52 week high

$38.85

$202.73

Open

John Francis Crowley

Founder of Amicus Therapeutics, Inc., Orexigen Therapeutics, Inc. and Novazyme Pharmaceuticals, Inc., John Francis Crowley is an entrepreneur and businessperson who has been at the helm of 5 different companies and occupies the position of Chairman & Chief Executive Officer for Amicus Therapeutics, Inc. and President at Scioderm, Inc. (a subsidiary of Amicus Therapeutics, Inc.). Mr. Crowley is also Member of The Wall Street Journal CEO Council and on the board of 5 other companies.

Mr. Crowley previously occupied the position of Director-Business Strategy at Bristol Myers Squibb Co., President & Chief Executive Officer for Orexigen Therapeutics, Inc., President & Chief Executive Officer for Novazyme Pharmaceuticals, Inc., Litigation Associate-Health Care Practice Group at Bingham Summers Welsh & Spilman, Senior Vice President of Genzyme Therapeutics Ltd. and National Chairman at Make-A-Wish Foundation of America.

He received an undergraduate degree from Georgetown University, a graduate degree from the University of Notre Dame The Law School and an MBA from Harvard Business School.

Transactions

Date Shares Transaction Value
10/11/2021 2,500   Disposition at $119.55 per share. 298,875
10/11/2021 2,500   Derivative/Non-derivative trans. at $18.83 per share. 47,075
10/05/2021 200   Disposition at $132.84 per share. 26,568
10/05/2021 1,846   Disposition at $131.74 per share. 243,193
10/05/2021 3,759   Disposition at $130.92 per share. 492,129
10/05/2021 2,915   Disposition at $129.88 per share. 378,601
10/05/2021 1,280   Disposition at $128.83 per share. 164,903
10/05/2021 10,000   Derivative/Non-derivative trans. at $18.83 per share. 188,300

Officers and Executives

Dr. John M. Leonard
President, Chief Executive Officer & Director
Mr. Glenn Goddard
Treasurer, Chief Financial & Accounting Officer
Dr. Laura Sepp-Lorenzino
Chief Scientific Officer & Executive VP
Dr. Eliana Clark
Chief Technology Officer & Executive VP
Dr. David Lebwohl
Chief Medical Officer & Executive Vice President
Dr. Christine Foster
SVP-Business Development & Alliance Management
Mr. Derek Hicks
Chief Business Officer & Executive Vice President
Mr. Ian Karp
Senior Vice President-Corporate Communications
Ms. Marika St Amand
Chief Human Resources Officer
Mr. James Basta
Secretary, Executive VP & General Counsel
Dr. Frank A. G. M. Verwiel
Chairman
Mr. John Francis Crowley
Independent Director
Dr. Georgia Keresty
Independent Director
Ms. Muna Bhanji
Independent Director
Dr. Jean-Francois B. Formela
Independent Director
Ms. Caroline D. Dorsa
Independent Director
Dr. Jesse L. Goodman
Independent Director
Dr. Fred Ehrenkranz Cohen
Independent Director
Link to MarketWatch's Slice.